Journal article icon

Journal article

Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE

Abstract:
Objectives
Evaluate the importance of treatment sequencing in SELECT-COMPARE, assessing potential differences between starting upadacitinib or adalimumab therapy following inadequate MTX response.
Methods
Patients from SELECT-COMPARE were randomized to upadacitinib 15 mg once daily, placebo or adalimumab 40 mg. Per protocol, patients with <20% improvement in tender or swollen joint counts (weeks 14, 18, 22) or failure to achieve Clinical Disease ... Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1093/rheumatology/keac477

Authors


More by this author
Role:
Author
ORCID:
0000-0002-8993-0313
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Botnar Research Centre
Oxford college:
St Peter's College
Role:
Author
ORCID:
0000-0001-7766-6167
Publisher:
Oxford University Press
Journal:
Rheumatology More from this journal
Volume:
62
Issue:
5
Pages:
1804–1813
Publication date:
2022-08-26
Acceptance date:
2022-08-11
DOI:
EISSN:
1462-0332
ISSN:
1462-0324
Language:
English
Keywords:
Pubs id:
1276590
Local pid:
pubs:1276590
Deposit date:
2022-09-01

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP